Search

Displaying results 301 - 310 of 392 in total
  1. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    [L12621,L12627] Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections.

  2. Drug

    Somatotropin

    go.drugbank.com/drugs/DB00052
    ApprovedInvestigational

    [A228188] Recombinant growth hormone is available as a subcutaneous injection for children and adults under a wide variety of brand names.

  3. Drug

    Pyrethrum extract

    go.drugbank.com/drugs/DB11087
    Approved

    Pyrethrum is the crude extract form obtained from flowers of the plant Chrysanthemum cinerariifolium. Pyrethrin refers to a more refined extract of pyrethrum. While pyrethrum extract is composed of 6 esters, both organic compounds mediat...

    Mixtures: Select Brand Lice Killing
  4. Drug

    Lactulose

    go.drugbank.com/drugs/DB00581
    ApprovedInvestigational

    [L6202] Nevertheless, although lactulose received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health

    Products: LATTULOSIO MYLAN GENERICS
  5. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).

  6. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February 2021, under the brand

  7. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    [A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163]

  8. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    It is available under the brand name Olita made by Hanmi Pharmaceuticals [A19196]. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim.

  9. Drug

    Ripasudil

    go.drugbank.com/drugs/DB13165
    Investigational

    This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec.

  10. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [A244470,A244499] Sotagliflozin was approved by the EMA under the brand name "Zynquista" on April 26, 2019, for the treatment of type 1 diabetes.